drugset / Trial / NCT05764642
A Study of Renal Microvessel Imaging for Chronic Kidney Disease
Phase 2
Enrolling by invitation
186 enrolled
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.
Timeline
- Start
- 2023-08-09
- Primary completion
- 2028-04-01
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Definity | Diagnostic / imaging agent | — | Intravenous |